Alnylam Pharmaceuticals this week announced that it has closed its previously announced acquisition of Merck's RNAi assets, including its Sirna Therapeutics subsidiary.
Merck, which acquired Sirna in 2007 for $1.1 billion, unveiled a company-wide restructuring last year that included a reduction in emphasis on platform technologies, including RNAi. In January, the company disclosed that it would sell its RNAi assets to Alnylam in exchange for $25 million in cash and $150 million in stock.